Thus, evaluating ChT outcomes and DEGs from the intersections of several appropriate datasets could reveal comprehensive hubs of S1R involvement while controlling for tumor heterogeneities and co‐treatments. This evidence concerns the gene SLC5A7 and neoplasm.